XML 53 R42.htm IDEA: XBRL DOCUMENT v3.4.0.3
Long-Term Contingent Consideration Payable (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Dec. 31, 2015
Business Acquisition, Contingent Consideration [Line Items]      
Additions $ 7,695    
Payments to Related Parties (9,106)    
Operating Expense; Acquisition-Related 7,916 $ 5,254  
Interest Expense; Financing-Related 1,861    
Total contingent consideration 131,059   $ 122,693
Less: Current portion 28,403   28,614
Total long-term contingent consideration payable 102,656   $ 94,079
Warrant [Member] | Acquisition-related Costs [Member]      
Business Acquisition, Contingent Consideration [Line Items]      
Business Combination,Beginning [1] 20,617    
Additions [1] 0    
Payments to Related Parties [1] 0    
Operating Expense; Acquisition-Related [1] (3,535)    
Interest Expense; Financing-Related [1] 0    
Business Combination,Ending [1] 17,082    
Earn Out Payments [Member] | Acquisition-related Costs [Member]      
Business Acquisition, Contingent Consideration [Line Items]      
Business Combination,Beginning [2] 90,468    
Additions [2] 0    
Payments to Related Parties [2] (8,014)    
Operating Expense; Acquisition-Related [2] 11,451    
Interest Expense; Financing-Related [2] 0    
Business Combination,Ending [2] 93,905    
Deerfield Royalty agreement [Member] | Financing Related Costs [Member]      
Business Acquisition, Contingent Consideration [Line Items]      
Business Combination,Beginning [3] 7,862    
Additions [3] 0    
Payments to Related Parties [3] (739)    
Operating Expense; Acquisition-Related [3] 0    
Interest Expense; Financing-Related [3] 1,038    
Business Combination,Ending [3] 8,161    
Broadfin Royalty agreement [Member] | Financing Related Costs [Member]      
Business Acquisition, Contingent Consideration [Line Items]      
Business Combination,Beginning [4] 3,746    
Additions [4] 0    
Payments to Related Parties [4] (353)    
Operating Expense; Acquisition-Related [4] 0    
Interest Expense; Financing-Related [4] 496    
Business Combination,Ending [4] 3,889    
FSC Royalty Agreement [Member] | Financing Related Costs [Member]      
Business Acquisition, Contingent Consideration [Line Items]      
Business Combination,Beginning [5] 0    
Additions [5] 7,695    
Payments to Related Parties [5] 0    
Operating Expense; Acquisition-Related [5] 0    
Interest Expense; Financing-Related [5] 327    
Business Combination,Ending [5] $ 8,022    
[1] As part of the consideration for the Company’s acquisition of Éclat Pharmaceuticals, LLC on March 13, 2012, the Company issued two warrants with a six-year term which allow for the purchase of a combined total of 3,300 ordinary shares of Flamel. One warrant is exercisable for 2,200 shares at an exercise price of $7.44 per share, and the other warrant is exercisable for 1,100 shares at an exercise price of $11.00 per share.
[2] As part of the consideration for the Company’s acquisition of Éclat Pharmaceuticals, LLC in March 2012, the Company committed to provide quarterly earn-out payments equal to 20% of any gross profit generated by certain Éclat Pharmaceuticals products. These payments will continue in perpetuity, to the extent revenues of the related product also continue in perpetuity.
[3] As part of a February 2013 debt financing transaction conducted with Deerfield Management, a related party and current shareholder, the Company received cash of $2,600 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 1.75% royalty on the net sales of certain Éclat Pharmaceuticals products until December 31, 2024.
[4] As part of a December 2013 debt financing transaction conducted with Broadfin Healthcare Master Fund, a related party and current shareholder, the Company received cash of $2,200 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 0.834% royalty on the net sales of certain Éclat Pharmaceuticals products until December 31, 2024.
[5] As part of the consideration for the Company’s acquisition of FSC Holdings, LLC in February 2016, the Company entered into a royalty agreement whereby the Company shall pay quarterly a 15% royalty on the net sales of certain FSC products, up to $12,500 for a period not exceeding ten years.